{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:32:49Z","timestamp":1793212369781,"version":"4.5.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Acquired hemophilia A (AHA) is a severe bleeding disorder caused by neutralizing autoantibodies against coagulation factor VIII (FVIII). Standard treatment involves immunosuppressive therapy (IST), which carries a significant risk of serious infections, the leading cause of death in patients with AHA. The GTH-AHA-EMI study investigated the use of emicizumab to prevent bleeding during the first 12 weeks of management while postponing IST. We collected 2-year follow-up data from GTH-AHA-EMI patients (n = 47) and compared outcomes to a propensity score (PS)\u2013matched cohort from the GTH-AH 01\/2010 study (n = 101), in which patients received immediate IST. Outcome measures included overall survival (OS), infection- and bleed-related mortality, and time to complete remission (CR). The study cohorts were well-matched in age, sex, underlying conditions, baseline FVIII activity, inhibitor titer, and performance status. The PS-matched 2-year OS was 82% in the GTH-AHA-EMI cohort vs 63% in GTH-AH 01\/2010 (hazard ratio, 0.39; 95% confidence interval, 0.19-0.80). Infection-related mortality was lower with emicizumab (4% vs 16%), whereas bleed-related mortality was similar (4% vs 3%). Spontaneous remission of AHA occurred in 15% of GTH-AHA-EMI patients. Time to CR estimated by the Kaplan-Meier method was longer with postponed IST in GTH-AHA-EMI (44 vs 16 weeks), but the estimated proportion of patients achieving CR was similar (76% vs 66%). In conclusion, emicizumab allowed for postponed IST initiation during early AHA management in the GTH-AHA-EMI study. Delayed IST was safe and effective. Compared to PS-matched historic controls receiving immediate IST but no emicizumab, GTH-AHA-EMI patients had fewer fatal infections and improved OS. This trial was registered at www.ClinicalTrials.gov as #NCT04188639.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017144","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T20:05:44Z","timestamp":1755029144000},"page":"5853-5860","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A"],"prefix":"10.1182","volume":"9","author":[{"given":"Inga M.","family":"Schimansky","sequence":"first","affiliation":[{"name":"1Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Dobbelstein","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4194-8183","authenticated-orcid":false,"given":"Robert","family":"Klamroth","sequence":"additional","affiliation":[{"name":"2Department of Internal Medicine, Vivantes Clinic Friedrichshain, Berlin, Germany"},{"name":"3Institute of Experimental Hematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Hart","sequence":"additional","affiliation":[{"name":"4Department of Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich J.","family":"Sachs","sequence":"additional","affiliation":[{"name":"5Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[{"name":"6Internal Medicine III, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7909-7225","authenticated-orcid":false,"given":"Paul","family":"Kn\u00f6bl","sequence":"additional","affiliation":[{"name":"7Division of Hematology and Hemostasis, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1585-4100","authenticated-orcid":false,"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"3Institute of Experimental Hematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4506-0061","authenticated-orcid":false,"given":"Wolfgang","family":"Miesbach","sequence":"additional","affiliation":[{"name":"8Medical Clinic II, Institute of Transfusion Medicine, Goethe University, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0485-7402","authenticated-orcid":false,"given":"Christian","family":"Pfrepper","sequence":"additional","affiliation":[{"name":"9Division of Hemostaseology, Medical Department I, University Hospital Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolin","family":"Trautmann-Grill","sequence":"additional","affiliation":[{"name":"10Medical Clinic I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"M\u00f6hnle","sequence":"additional","affiliation":[{"name":"11Department of Transfusion Medicine, Cellular Therapeutics and Hemostaseology, Department of Anesthesiology, Hospital of Ludwig Maximilian University, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Holstein","sequence":"additional","affiliation":[{"name":"12Institute of Clinical Chemistry, University Medical Center Schleswig-Holstein, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Eichler","sequence":"additional","affiliation":[{"name":"13Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University and Saarland University Hospital l, Saarbr\u00fccken, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Werwitzke","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3600-8536","authenticated-orcid":false,"given":"Andreas","family":"Tiede","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"7","key":"2025112509112173800_bib1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.24777","article-title":"Acquired hemophilia A: updated review of evidence and treatment guidance","volume":"92","author":"Kruse-Jarres","year":"2017","journal-title":"Am J Hematol"},{"issue":"5","key":"2025112509112173800_bib2","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2006-06-029850","article-title":"Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation","volume":"109","author":"Collins","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2025112509112173800_bib3","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1111\/hae.14149","article-title":"The rising incidence of acquired haemophilia A in Germany","volume":"27","author":"Tiede","year":"2021","journal-title":"Haemophilia"},{"issue":"2","key":"2025112509112173800_bib4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hae.12627","article-title":"Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A","volume":"21","author":"Kruse-Jarres","year":"2015","journal-title":"Haemophilia"},{"issue":"4","key":"2025112509112173800_bib5","first-page":"312","article-title":"Susoctocog-alfa (Obizur\u00ae) in the treatment of nine elderly patients with acquired haemophilia A: an Italian multicentre real world experience","volume":"18","author":"Zanon","year":"2020","journal-title":"Blood Transfus"},{"issue":"3","key":"2025112509112173800_bib6","first-page":"279","article-title":"Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"136","author":"Holstein","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2025112509112173800_bib7","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bjh.15175","article-title":"Activated prothrombin complex concentrate (FEIBA\u00ae) in acquired haemophilia A: a large multicentre Italian study - the FAIR Registry","volume":"184","author":"Zanon","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"2025112509112173800_bib8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11239-018-1750-y","article-title":"Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired haemophilia A: data from FAIR Registry","volume":"47","author":"Pasca","year":"2019","journal-title":"J Thromb Thrombolysis"},{"issue":"10","key":"2025112509112173800_bib9","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00277-018-3372-z","article-title":"Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia","volume":"97","author":"Tiede","year":"2018","journal-title":"Ann Hematol"},{"issue":"10","key":"2025112509112173800_bib10","first-page":"e19145","article-title":"Management of acquired factor VIII inhibitors with NovoSeven and Obizur","volume":"13","author":"Miatech","year":"2021","journal-title":"Cureus"},{"issue":"4","key":"2025112509112173800_bib11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.5482\/HAMO-14-11-0064","article-title":"Management of acquired haemophilia A","volume":"35","author":"Tiede","year":"2015","journal-title":"Hamostaseologie"},{"issue":"7","key":"2025112509112173800_bib12","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood-2014-07-587089","article-title":"Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01\/2010 study","volume":"125","author":"Tiede","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2025112509112173800_bib13","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"2025112509112173800_bib14","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/hae.15037","article-title":"Acquired haemophilia A in Finland: A nationwide study of incidence, treatment and outcomes","volume":"30","author":"Nummi","year":"2024","journal-title":"Haemophilia"},{"issue":"19","key":"2025112509112173800_bib15","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/bloodadvances.2021004626","article-title":"Management of acquired hemophilia A: results from the Spanish registry","volume":"5","author":"Mingot-Castellano","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"2025112509112173800_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ajh.26009","article-title":"Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study","volume":"96","author":"Schep","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"2025112509112173800_bib17","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/hae.12138","article-title":"Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l'Hemophilie Acquise) registry","volume":"19","author":"Borg","year":"2013","journal-title":"Haemophilia"},{"issue":"9","key":"2025112509112173800_bib18","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"2025112509112173800_bib19","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jtha.2022.10.004","article-title":"A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A","volume":"21","author":"Shima","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2025112509112173800_bib20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1055\/a-2384-3585","article-title":"Final analysis results from the AGEHA study: emicizumab prophylaxis for acquired hemophilia A with or without immunosuppressive therapy","volume":"125","author":"Shima","year":"2025","journal-title":"Thromb Haemost"},{"issue":"11","key":"2025112509112173800_bib21","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1016\/S2352-3026(23)00280-6","article-title":"Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study","volume":"10","author":"Tiede","year":"2023","journal-title":"Lancet Haematol"},{"issue":"10","key":"2025112509112173800_bib22","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1016\/j.jtha.2024.06.010","article-title":"Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A","volume":"22","author":"Hart","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2025112509112173800_bib23","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/jth.15208","article-title":"Should emicizumab be used in patients with acquired hemophilia A?","volume":"19","author":"Tiede","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2025112509112173800_bib24","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jtha.2024.09.040","article-title":"Acquired hemophilia A: a narrative review and management approach in the emicizumab era","volume":"23","author":"Ellsworth","year":"2025","journal-title":"J Thromb Haemost"},{"key":"2025112509112173800_bib25","author":"R Core Team","year":"2024"},{"issue":"4","key":"2025112509112173800_bib26","doi-asserted-by":"crossref","first-page":"102438","DOI":"10.1016\/j.rpth.2024.102438","article-title":"Emicizumab as first-line therapy in acquired hemophilia A","volume":"8","author":"Iarossi","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2025112509112173800_bib27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/hematology.2023000462","article-title":"The role of emicizumab in acquired hemophilia A","volume":"2023","author":"Poston","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"7","key":"2025112509112173800_bib28","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood-2014-12-618959","article-title":"The problem of acquired hemophilia","volume":"125","author":"Baudo","year":"2015","journal-title":"Blood"},{"key":"2025112509112173800_bib29","doi-asserted-by":"crossref","first-page":"10760296241298661","DOI":"10.1177\/10760296241298661","article-title":"Outcomes of emicizumab in acquired hemophilia patients: a systematic review","volume":"30","author":"Ikbel","year":"2024","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"2025112509112173800_bib30","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.2008.001743","article-title":"International recommendations on the diagnosis and treatment of patients with acquired hemophilia A","volume":"94","author":"Huth-K\u00fchne","year":"2009","journal-title":"Haematologica"},{"issue":"11","key":"2025112509112173800_bib31","doi-asserted-by":"crossref","first-page":"e870","DOI":"10.1016\/S2352-3026(23)00303-4","article-title":"Rapidly loading emicizumab without immunosuppression in acquired haemophilia","volume":"10","author":"Ragni","year":"2023","journal-title":"Lancet Haematol"},{"issue":"6","key":"2025112509112173800_bib32","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1055\/a-2197-9738","article-title":"Emicizumab for the treatment of acquired hemophilia A: consensus recommendations from the GTH-AHA Working Group","volume":"44","author":"Pfrepper","year":"2024","journal-title":"Hamostaseologie"},{"issue":"6","key":"2025112509112173800_bib33","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/archinte.1987.00370060073014","article-title":"Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy","volume":"147","author":"Lottenberg","year":"1987","journal-title":"Arch Intern Med"},{"issue":"9","key":"2025112509112173800_bib34","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1007\/s00277-020-04150-y","article-title":"Reduced-intensity, risk factor-stratified immunosuppression for acquired hemophilia A: single-center observational study","volume":"99","author":"Dobbelstein","year":"2020","journal-title":"Ann Hematol"},{"issue":"18","key":"2025112509112173800_bib35","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1182\/blood.2022016873","article-title":"Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen","volume":"140","author":"Simon","year":"2022","journal-title":"Blood"},{"issue":"22","key":"2025112509112173800_bib36","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1182\/bloodadvances.2024013882","article-title":"Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohort","volume":"8","author":"Poston","year":"2024","journal-title":"Blood Adv"},{"issue":"18","key":"2025112509112173800_bib37","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1200\/JCO.2004.01.078","article-title":"Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection","volume":"22","author":"Santolaya","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025112509112173800_bib38","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jvir.2019.10.017","article-title":"Length of stay predicts risk of early infection for hospitalized patients undergoing central venous port placement","volume":"31","author":"Tang","year":"2020","journal-title":"J Vasc Interv Radiol"},{"key":"2025112509112173800_bib39","author":"Fleiss","year":"2003"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/22\/5853\/2420530\/blooda_adv-2025-017144-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/22\/5853\/2420530\/blooda_adv-2025-017144-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:11:34Z","timestamp":1764079894000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/22\/5853\/546661\/Sustained-survival-benefit-of-emicizumab-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":39,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025,11,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017144","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,25]]},"published":{"date-parts":[[2025,11,14]]}}}